Jacob Gottlieb studied Economics at Brown University and medicine at New York University Medical School. Gottlieb is also considered Chartered Financial Analyst a designation achieved in 2001. By 2010, he would use Professional Risk Managers’ International Association to be categorized as Professional Risk Manager. His education and credentials have helped him as an entrepreneur with several business ventures. Altium Capital (AC) is the latest venture, but Gottlieb is a founder of Visium Asset Management, LLC, and Balyasny Asset Management, L.P.
AC makes investments in growing companies that work within the healthcare industry. AC has invested in companies such as Oramed Pharmaceuticals (ORMP), Amarin Corporation (AMRN), Oragenics, and Sellas Life Sciences (SLS). AC made 5.6 percent investment in ORMP because the company is developing an oral drug delivery system that delivers medicine to a person with diabetes that would be normally injected. The use of an oral drug delivery system will reduce the risk of infection. AMRN is a company that develops drugs that promotes cardiovascular health. AMRN’s expertise helped them create a prescription drug called Amarin’s Vascepa, and it used to treat hypertriglyceridemia. Oragenics creates tests that are easy to used by a person without medical training. The tests are used to detect life-threatening diseases and conditions. SLS developed Wilms Tumor Protein (WT1)-targeting immunotherapeutic. They also use other drugs to combat one most aggressive cancer, triple negative breast cancer.
Gottlieb not only was an entrepreneur, but he was a portfolio manager and analyst. As an analyst, Gottlieb would spend two years analyzing global healthcare. Visium Asset Management was a hedge fund that Gottlieb founded in 2005. It grew to over $8 billion. It would be in 2016 the fund would face an insider-trading scandal, but Gottlieb was able to avoid scandal. Gottlieb also was able to make contributions and times to in a variety of philanthropic projects that help programs educate youth.